logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Difeng Group Auto (06878) will have its listing status cancelled starting from October 27.

date
22/10/2026
Zhitong Finance APP News, Differ Group Auto (06878) issued an announcement that The Stock Exchange of Hong Kong Limited (the Stock Exchange) announced that with effect from 9:00 a.m. on October 27, 2026, the listing status of Differ Group Auto Limited (in liquidation) (the Company) will be cancelled under Rule 6.01A(1) of the Listing Rules.
Latest
4 m ago
Changqing Shares (002391.SZ) released its first three quarters performance, with net profit attributable to the parent company of 60.8178 million yuan, a year-on-year increase of 16.3%.
5 m ago
Xiduoli Technology (688582.SH) released its performance for the first three quarters, with net profit attributable to the parent company of 34.6684 million yuan, a year-on-year decrease of 85.48%.
7 m ago
Wells Fargo: Cuts price target on Meta Platforms from $1,000 to $995.
8 m ago
Yongxing Materials (002756.SZ) released its first three quarters performance, with net profit attributable to the parent company of 1.378 billion yuan, a year-on-year increase of 159.26%.
9 m ago
Hengrui Medicine (600276.SH): Ruiweilutamide Tablets Receives Drug Clinical Trial Approval Notice
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.